NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its earnings results on Thursday, October, 31st. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.14 by $0.10. The business earned $605.30 million during the quarter, compared to analysts' expectations of $597.09 million. IDEXX Laboratories had a return on equity of 405.71% and a net margin of 17.99%. IDEXX Laboratories's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.05 EPS. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Friday, January 31st 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories will be holding an earnings conference call on Friday, January 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

IDEXX Laboratories issued an update on its FY20 earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $5.30-5.46 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.56. The company issued revenue guidance of $2.61-2.65 billion, compared to the consensus revenue estimate of $2.63 billion.

6 equities research analysts have issued 1-year target prices for IDEXX Laboratories' stock. Their forecasts range from $277.00 to $310.00. On average, they anticipate IDEXX Laboratories' stock price to reach $293.33 in the next year. This suggests a possible upside of 2.6% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

Media stories about IDXX stock have been trending very positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IDEXX Laboratories earned a coverage optimism score of 3.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for IDEXX Laboratories.

IDEXX Laboratories saw a drop in short interest in the month of December. As of December 13th, there was short interest totalling 1,310,000 shares, a drop of 10.3% from the November 28th total of 1,460,000 shares. Based on an average daily volume of 463,700 shares, the short-interest ratio is presently 2.8 days. Approximately 1.6% of the company's stock are short sold. View IDEXX Laboratories' Current Options Chain.

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Netflix (NFLX), Adobe (ADBE), Alibaba Group (BABA), Mastercard (MA), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and Walt Disney (DIS).

IDEXX Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Welch & Forbes LLC (0.21%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.17%), Howland Capital Management LLC (0.15%), Davis R M Inc. (0.14%), Chicago Capital LLC (0.11%) and Nisa Investment Advisors LLC (0.07%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, DNB Asset Management AS, First Hawaiian Bank, Davis R M Inc., Cribstone Capital Management LLC, State of Alaska Department of Revenue and Calamos Wealth Management LLC. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Mckinley Capital Management LLC Delaware, Johanson Financial Advisors Inc., Aurora Investment Managers LLC., Pensionfund DSM Netherlands, Chapman Investment Management LLC, Ambassador Advisors LLC and Pensionfund Sabic. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $285.90.

IDEXX Laboratories has a market capitalization of $24.52 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.

The official website for IDEXX Laboratories is http://www.idexx.com/.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]